According to the World Health Organization, cardiovascular disease (CVD) remains the
leading cause of death worldwide, accounting for approximately 18 million deaths per year …

Background Non-alcoholic fatty liver disease (NAFLD) is an emerging disease and a
leading cause of chronic liver disease. The prevalence in the general population is …

摘要非酒精性脂肪性肝病(Non‐alcoholic fatty liver disease, NAFLD) 是西方国家最常见的肝脏
疾病, 在普通人群中的患病率约为20%–33%. 我国已报道的研究数据显示 …

Non-alcoholic fatty liver disease (NAFLD) is one of the most common comorbidities
associated with overweight and metabolic syndrome (MetS). Importantly, NAFLD is one of its …

Background & Aims Little is known about outcomes of patients with nonalcoholic
steatohepatitis (NASH) who receive liver transplants. We performed a systematic review and …

There have been several reports about the clinical association between type 2 diabetes
mellitus (DM) and nonalcoholic fatty liver disease (NAFLD). However, most of the studies …

Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) are two
diseases that are common in the general population. To date, many studies have been …

Triacyglycerols are a major energy reserve of the body and are normally stored in adipose
tissue as lipid droplets (LDs). The liver, however, stores energy as glycogen and digested …

Follistatin (Fst) functions to bind and neutralize the activity of members of the transforming
growth factor-β superfamily. Fst has a well-established role in skeletal muscle, but we …

There is a paucity of recent data about the epidemiology and long‐term outcomes of
nonalcoholic fatty liver disease (NAFLD) in the female population. Our aim was to assess the …